RxDoctor Payments Data

Michael Prevost, MD

Family Medicine · Ishpeming, MINPI 1689735698

Payments from drug & device makers

$478in general payments, 2019–2025

Across 27 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$122
  • Novo Nordisk$105
  • Merck$93
  • GSK$67
  • Abbott$47
  • Boehringer Ingelheim$17
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$478100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca5$122
Novo Nordisk7$105
Merck5$93
GSK5$67
Abbott2$47
Boehringer Ingelheim1$17
Medtronic1$14
Lilly USA, LLC1$13

How this compares

$478 in reported general payments places this provider in the 60th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$115,611
Medicare patients
302
Services billed
1,586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban109$122,161
XareltoRivaroxaban86$91,159
OzempicSemaglutide70$85,494
JardianceEmpagliflozin59$71,871
Trelegy ElliptaFluticasone/Umeclidin/Vilanter86$67,571
MounjaroTirzepatide13$22,558
TrulicityDulaglutide18$17,801
ShingrixVaricella-Zoster Ge/As01b/Pf60$12,819
JanuviaSitagliptin Phosphate12$10,748
Humalog Kwikpen U-100Insulin Lispro26$10,392
Combivent RespimatIpratropium/Albuterol Sulfate11$8,909
Breo ElliptaFluticasone/Vilanterol13$8,867
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$6,930
Novolog FlexpenInsulin Aspart19$6,596
Tiotropium Bromide14$6,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Arexvy$67$93,847176 claims
Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat$17$86,39882 claims
Novo NordiskOzempic$105$85,49470 claims
Lilly USA, LLCMounjaro, Trulicity$13$40,35931 claims
MerckJanuvia$93$10,74812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Ishpeming

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →